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Abstract
Background: Along with the development of new cancer therapeutics, more effective tools for
the estimation of response to therapy and prediction of disease progression are required for the
better management of inoperable cancer patients.
Methods: We studied 134 newly diagnosed and primarily untreated advanced non-small cell lung
cancer patients and 100 controls. Forty two patients received platinum-based chemotherapy.
Plasma VEGF levels were quantified in all samples at baseline and also before second and third
chemotherapy cycle in 42 patients and correlated with response to therapy as assessed by
computed tomography after the third chemotherapy cycle.
Results: We observed that, patients who went into remission had significantly lower baseline
VEGF levels before second and third cycles of chemotherapy when compared with patients with
no change and progression. Plasma VEGF levels showed a greater decrease from cycle 1 to 2 and
from cycle 1 to 3 in patients who showed remission in comparison to those with no change or
progression. Plasma VEGF levels before the second cycle detected poor response to therapy with
a sensitivity and specificity of 76.9% and 75.0%, respectively (area under the ROC curve = 0.724).
Early prediction of disease progression was achieved with a sensitivity and specificity of 71.4% for
plasma VEGF before cycle 2 (area under the ROC curve = 0.805). The kinetics of VEGF form cycle
1 to 2 and cycle 1 to 3 also gave significant information for predicting disease progression as well
as insufficient therapy response.
Conclusion: Monitoring of plasma VEGF levels during the course of first-line chemotherapy could
identify patients who are likely to have insufficient response to therapy and disease progression at
an early stage. This may help in individualizing treatment and could lead to better management of
the advanced stage lung cancer.
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Lung cancer is one of the commonest neoplasms all over
the world with approximately 1.35 million new cases
worldwide in 2002 [1]. It is the most devastating cause of
cancer-related deaths with more than 1.18 million deaths
in 2002 [1]. Survival at 5 years measured by the SEER pro-
gram in the United States is 15%, the best recorded at the
population level. The average 5 year survival in Europe is
10%, not much better than the 8.9% observed in develop-
ing countries [1]. The poor outcome is attributable to the
fact that almost two-third of cases are diagnosed when
loco-regional and/or metastatic extension has already
occurred [2]. The only treatment available at this stage is
chemotherapy and/or radiotherapy. Although response
rates for chemotherapy and radiotherapy are low, several
studies have demonstrated moderate beneficial effects
concerning survival, time to disease progression, and
quality of life when compared with best supportive care
[3]. The current staging investigations after cytotoxic ther-
apies, like chemotherapy and/or radiotherapy, involve
imaging procedures, like computed tomography (CT) and
positron-emission tomography (PET)-CT. However, these
procedures can monitor only macroscopic alteration of
tumor mass, that too after several cycles of chemotherapy
(2-3 cycles of chemotherapy and/or radiotherapy). In
addition, they also have a risk of exposure to harmful radi-
ation to the patient. Thus, there is a growing need for a
simple tool that can help in evaluating the prognosis,
monitor the effect of treatment and most importantly pre-
dict response to therapy at an early stage. One potential
approach could be the quantification of tumor markers as
they take into account the heterogeneity of the tumor
mass which contain active, silent, apoptotic and necrotic
part and they also represent the activity of the residual
tumor disease. Therefore, any change in their levels
should reflect the change in the tumor mass due to cyto-
toxic therapies, which mean that they can potentially pro-
vide a sensitive and cost-effective method for the
prediction of prognosis of cancer patients. Further, serial
assessment of tumor markers during cytotoxic therapies
may help in predicting response to therapy at an early
stage. This would help in optimizing disease management
on an individual basis. In non-small cell lung cancer
patients, several tumor markers, like CEA, CYFRA 21-1,
and nucleosomes have shown considerable potential for
predicting diagnosis, prognosis and therapy monitoring
[4-9]. However, their potential in a clinical set-up is yet to
be realized.
There is now an increasing recognition of the importance
of targeted therapies, especially anti-angiogenesis thera-
pies, in solid tumors to improve the overall survival or
progression free survival. The two most common
approaches currently being explored are i) antibodies to
vascular endothelial growth factor (VEGF) or soluble
receptors that inhibit the binding of VEGF to its receptor
and ii) tyrosine kinase inhibitors blocking downstream
signaling from membrane bound tyrosine kinase recep-
tors. It is therefore becoming essential to study the profile
of circulating VEGF during cytotoxic therapies in an effort
to evaluate its potential in predicting prognosis, response
to therapy, and disease progression. We hypothesized that
monitoring VEGF levels during the course of cytotoxic
therapy may have the potential to predict the clinical ben-
efits in terms of prognosis and response to therapy in
advanced NSCLC patients.
In the present study, we investigated the plasma levels of
VEGF in a homogeneous group of patients with newly
diagnosed and advanced NSCLC during first-line plati-
num-based chemotherapy to analyze the utility of VEGF
for the prediction of insufficient response to therapy and
disease progression. In addition, we looked for any corre-
lation between pre-treatment plasma levels of VEGF with
various clinico-pathological parameters in patients with
non-small cell lung cancer.
Methods
Subjects
We evaluated 134 newly diagnosed and primarily
untreated advanced stage lung cancer patients and 100
age-matched controls (patients without malignancy). All
subjects were enrolled from Out Patient Department of
Medicine, All India Institute of Medical Sciences, New
Delhi, India between years 2006-2009. For all patients, a
diagnosis of lung cancer was confirmed by the histologic
examinations of biopsy and/or cytology specimens
obtained during fiberoptic bronchoscopy or with a CT-
guided procedure. Pre-treatment evaluation also included
evaluation of Eastern Cooperative Oncology Group per-
formance status (ECOG), X-ray and computed tomogra-
phy (CT) scan of the chest and upper abdomen. If
necessary, a CT or magnetic resonance imaging (MRI)
scan of the brain, and radionuclide bone scan was per-
formed. All the patients were staged according to the
American Thoracic Society TNM classification [10]. Epide-
miological data including demographics, family history,
risk factors, occupational exposure, and histopathological
data was recorded. Forty two (42) of these patients
received platinum-based chemotherapy for a minimum of
3 cycles. In these patients, response to therapy was classi-
fied according to the WHO guidelines defining "partial
remission" (R) as tumor reduction ≥ 50%, "progression"
(P) as tumor increase ≥ 25% or appearance of new tumor
manifestations, and "no change" (NC; stable disease) as
tumor reduction <50% or increase <25% [11].
Measurement of circulating plasma VEGF
Venous blood was collected in sterile EDTA-coated vials
from all subjects at baseline (BV1). Blood was also col-Page 2 of 12
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chemotherapy from 42 patients receiving platinum-based
chemotherapy. Within one hour, samples were centri-
fuged (2500 g, 10 min), and the plasma was removed,
aliquoted and stored at -80°C until analysis. The VEGF
was assayed by commercially available sandwich enzyme-
linked immunosorbent assay kits (Calbiochem, Darm-
stadt, Germany) according to the manufacturer's instruc-
tions. The limit of sensitivity of the VEGF assay was 9.0 pg/
mL. The coefficient of variation was less than 5.0%. The
study was approved by the institute's ethics committee.
Informed written consent was obtained from all the sub-
jects.
In the present study, we compared plasma VEGF levels in
patients with progressive disease (P) with those having
remission and stable disease (R+NC) to predict disease
progression (evaluation 1). Also, plasma VEGF levels in
patients with remission (R) were compared with those
having progressive and stable disease (P+NC) in an effort
to predict insufficient response to therapy (evaluation 2).
Statistical analysis
To test the association of therapy at time of staging inves-
tigations after 3rd cycle of chemotherapy with overall sur-
vival of the patients, Kaplan-Meier curves and log-rank
analyses were established for various response groups.
Concerning the biochemical variables, the baseline values
of all markers before the first, second, and third cycles
(BV1, BV2, and BV3) and the percentage changes (BV1-2
and BV1-3) were considered for statistical analyses. In a
first step, all biomarkers were evaluated on their power to
univariately discriminate between (a) patients with pro-
gression (P) and non-progression (R + NC; evaluation 1)
as well as between (b) patients with remission (R) and
non-remission (P + NC; evaluation 2) by Wilcoxon test.
To identify the diagnostic biomarker for insufficient ther-
apeutic efficacy and progression, receiver operating char-
acteristic curves and corresponding areas under the curve
(AUC) was calculated. In addition, sensitivity and specifi-
city (with 95% confidence interval) was calculated at
defined cut-off VEGF levels for detecting insufficient ther-
apeutic efficacy and progression.
Demographic information between cases and controls
was compared using unpaired t-test for continuous varia-
bles and Chi-square test for categorical variables. The
comparison of the different patient groups and the circu-
lating VEGF variables was performed using unpaired t-
test. All statistical comparisons for VEGF were performed
with logarithmically transformed data as VEGF-values
were not distributed normally. Median and interquartile
ranges for VEGF is given because of their skewed distribu-
tions. p value < 0.05 was considered statistically signifi-
cant. All statistical analyses were performed using SPSS
software program for Windows (SPSS 9.1; STATA Corpo-
ration, Texas, 77845, USA).
Results
Subject characteristics
The general characteristics of the patients and controls are
given in table 1. The median age was 56.5 years (range:
33-85) in non-small cell lung cancer (NSCLC) patients
and 56.5 years (range: 35-86) in controls. One hundred
and twenty one (90.3%) patients were male, while sev-
enty eight (78.0%) controls were male. Twenty six
(19.4%) patients and 33 (33.0%) controls were never
smokers. The demographic characteristics of NSCLC
patients and controls were significantly different for sex
and smoking status. The characteristics of patients with
NSCLC, like performance status, histology, stage, tumor
size, nodal status, presence of metastasis, smoking and
tobacco habits are given in table 2. Briefly, there were 103
patients with squamous cell carcinoma, and 31 with ade-
nocarcinoma. According to TNM classification, 87
patients had stage III disease and 47 patients had stage IV
disease.
Correlation of patient's characteristics with survival
At staging investigations after third cycle of chemother-
apy, 16 (38.1%) of the 42 patients had partial remission,
Table 1: Characteristics of the subjects
Characteristics Cases (n = 134) Controls (n = 100)
Age (years), median (range)‡ 56.5 (33-85) 56.5 (35-86)
Sex#
Male 121 (90.3%) 78 (78.0%)
Female 13 (9.7%) 22 (22.0%)
Smoking status†
Never smokers 26 (19.4%) 33 (33.0%)
Smokers 108 (80.6%) 67 (67.0%)
VEGF levels (pg/mL) * 265.7 (155.7-408.0) 74.5 (40.3-132.0)
Median (25-75% quartile)
‡p = 0.642;# p = 0.009;† p = 0.026; * p < 0.0001Page 3 of 12
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ble disease. The median survival time was 370 days (95%
CI = 289.6-450.4). Kaplan-Meier curves for overall sur-
vival showed highly significant differences in patients
with remission (R), and no change (NC) or progression
(P) at time of staging investigations after the third therapy
cycle (p < 0.0029 between R and NC; p < 0.0001 between
R and P; Figure 1A) with median survival times of 528 (R),
328 (NC), and 327 (P) days, respectively. There was no
difference in overall survival time between patients with
no change and progression (p = 0.2857). For evaluation 1,
when patients with remission and stable disease (R+NC)
were compared with patients having progressive disease
(P), a significant difference in overall survival was
observed with median survival times 416 (R+NC) and
327 (P) days (p < 0.0005; Figure 1B). When patients with
remission (R) were compared with patients having pro-
gressive and stable disease (P+NC; evaluation 2), median
survival times were 528 (R) and 328 (P+NC) days (p <
0.0001; Figure 1C).
We also examined univariate survival analysis for varia-
bles including age, stage, T factor, nodal status, perform-
ance status, histology, smoking and tobacco habits and
plasma VEGF levels (Table 3). Patients with a pre-treat-
ment plasma VEGF levels < 275.2 pg/mL (median value)
had a median survival of 348.0 days (95% CI = 246.1-
449.9), while those with ≥ 275.2 had a median survival of
370.0 (95% CI = 288.3-451.7). The pre-treatment plasma
VEGF levels did not correlate with survival (p = 0.8852).
We observed a significant correlation between tobacco
habit and survival time (p = 0.022; Table 3). However, no
correlation between other prognostic factors with survival
was observed (Table 3).
Table 2: The relationship between clinicopathological factors and plasma VEGF levels
Plasma VEGF Levels, pg/mL
Characteristics No. (%) Median 25-75% Quartile p Value
Age
<60 79 (59) 267.4 169.5 - 454.0 0.465
>60 55 (41) 262.7 146.6-385.4
Sex
Male 121 (90.3) 264.0 154.0 - 392.6 0.151
Female 13 (9.7) 338.4 262.0 - 459.4
Smoking
Smokers 108 (80.6) 273.9 173.7 - 442.7 0.144
Never-smokers 26 (19.4) 257.1 120.7 - 354.5
ECOG
1 39 (29.1) 225.7 108.6 - 354.5 0.062
2-3 95 (70.9) 282.0 182.3 - 446.0
Histology
SCC 103 (76.9) 276.0 169.5 - 439.5 0.147
ADC 31 (23.1) 262.0 132.3 - 338.4
Stage
III 87 (64.9) 251.4 149.0 - 433.4 0.250
IV 47 (35.1) 276.0 214.0 - 399.4
Tumor Size
<3 cm 44 (32.8) 172.4 93.0 - 262.0 0.001
>3 cm 90 (67.2) 339.9 218.0 - 484.5
T Factor
T2-T3 66 (49.2) 270.9 149.0 - 379.0 0.653
T4 68 (50.8) 263.0 157.6 - 439.7
N Factor
N0-N1 65 (48.5) 245.7 121.4 - 360.7 0.082
N2-N3 69 (51.5) 285.7 192.0-439.5
M Factor
M0 87 (64.9) 251.4 149.0 - 433.4 0.250
M1 47 (35.1) 276.0 214.0 - 399.4
Tobacco
Yes 25 (18.7) 252.3 185.7 - 354.5 0.524
No 109 (81.3) 267.4 154.0 - 433.4
VEGF, vascular endothelial growth factor; ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer; SCC, squamous cell 
carcinoma; ADC, adenocarcinoma; T, tumor; N, node; M, metastasisPage 4 of 12
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groups
We quantified plasma VEGF levels before first (BV1), sec-
ond (BV2) and third (BV3) cycles of chemotherapy in 42
NSCLC patients and correlated it with response to ther-
apy. Except at cycle 1 (BV1), most patients with remission
had considerably lower baseline VEGF levels before the
various treatment cycles (BV2 and BV3) than patients with
no change and even more than patients with progressive
disease (Table 4 and Figure 2).
Correlation of therapy response and overall survivalFigure 1
Correlation of therapy response and overall survival. 1A, Kaplan-Meier survival curves for overall survival of patients 
with remission (R), no change (NC), and progression (P) at time of staging investigations after third therapy cycle. 1B, for eval-
uation 1, patients with progressive disease (P) were compared with patients having remission and stable disease (R + NC). 1C, 
for evaluation 2, patients with remission (R) were compared with patients having progressive and stable disease (P + NC).
Remission + No change
Progression
p<0.0005
Remission (R)
No change (NC)
Progression (P)
p<0.0029 for  R vs NC
p<0.0001 for  R vs P
p<0.2857 for  NC vs P 
p<0.0029 for  R vs NC
p<0.0001 for  R vs P
p=0-2857 for  NC vs P
Remission
No change + Progression
p<0.0001
Table 3: Univariate survival analysis of prognostic factors of NSCLC (n = 42)
Variables n Median survival (95% CI) (days) P
Age (years)
<60 27 370.0 (301.3-438.7) 0.665
≥ 60 15 333.0 (244.6-421.4)
Stage
III 23 416.0 (369.1-462.8) 0.163
IV 19 327. 0 (298.7-355.3)
T factor
T2-T3 17 431.0 (315.3-546.7) 0.051
T4 25 348.0 (248.3-447.6)
N factor
N0-N1 21 394.0 (312.2-475.8) 0.380
N2-N3 21 348.0 (310.1-385.9)
ECOG
1 30 403.0 (327.9-478.0) 0.130
2-3 12 333.0 (311.5-354.5)
Histology
SCC 31 367.0 (288.1-445.9) 0.270
ADC 11 394.0 (324.8-463.1)
Smoking habit
Smokers 36 370.0 (294.0-446.0) 0.745
Non-smokers 06 367.0 (248.7-485.3)
Tobacco habit
Yes 08 394.0 (352.3-435.6) 0.022
No 34 314.0 (266.0-362.0)
Plasma VEGF (median)
<275.2 pg/mL 21 348.0 (246.1-449.9) 0.885
≥ 275.2 pg/mL 21 370.0 (288.3-451.7)
T, tumor; N, nodal status; ECOG, Eastern Cooperative Oncology Group; VEGF, vascular endothelial growth factor; 95% CI, 95% confidence 
interval.Page 5 of 12
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pared between R+NC versus P (evaluation 1) and R versus
NC+P (evaluation 2), it was observed that pre-treatment
VEGF levels (BV1) could not predict insufficient response
to therapy and disease progression (Table 4). However,
baseline VEGF levels before cycle 2 (BV2) and cycle 3
(BV3) were significantly able to predict insufficient
response to therapy and disease progression. Addition-
ally, VEGF levels showed stronger decrease from cycle 1 to
2 (BV1-2), from cycle 1 to 3 (BV1-3), and from cycle 2 to
3 (BV2-3) in patients with remission than with no change
or progression (Table 4 and Figure 2). The fraction of
patients with lower VEGF levels at cycle 2 (BV2) compared
with at cycle 1 (BV1) in the various groups were 87.5%
(R), 41.7% (NC), and 14.3% (P) and at cycle 3 (BV3) were
100% (R), 50% (NC) and 7.1% (P), respectively.
VEGF levels during chemotherapy for predicting 
insufficient response to therapy and disease progression
To test the potential of VEGF levels as a biomarker for the
prediction of insufficient therapy response, we plotted
receiver-operating characteristics (ROC) curves for the val-
ues available before first (BV1), second (BV2) and third
(BV3) therapy cycle (Figure 3). We did not consider
plasma VEGF before cycle 1 (BV1) for predicting insuffi-
cient therapy response because of very low area under the
ROC curve (AUC = 0.339; standard error = 0.09; 95% CI
= 0.157-0.520). The cut-off value of plasma VEGF levels
before therapy cycle 2 (BV2) was determined as 232.1 pg/
mL using the ROC analysis (area under the curve = 0.724;
standard error = 0.087; 95% CI = 0.553-0.893) According
to this cut-off value, we could predict insufficient therapy
response with a sensitivity and specificity of 76.9% (95%
CI = 55.9-90.2) and 75.0% (95% CI = 47.4-91.7), respec-
tively (Table 5). Interestingly, we observed similar sensi-
tivity and specificity for plasma VEGF levels available
before therapy cycle 3 (BV3; area under the ROC curve =
0.817; standard error = 0.070; 95% CI = 0.679-0.956). For
the specific prediction of insufficient response to therapy,
we observed very low sensitivities of 3.8% and 11.5% at
100% specificity for the VEGF levels available before sec-
ond and third cycles of chemotherapy, respectively
We also tested the relevance of VEGF levels available
before first (BV1), second (BV2), and third (BV3) therapy
cycle in predicting disease progression (Figure 4). Because
of low value of plasma VEGF before cycle 1 (BV1) under
the ROC curve, we did not consider it for predicting dis-
ease progression (AUC = 0.552; standard error = 0.08;
95% CI = 0.376-0.729). However, plasma VEGF at BV2
and BV3 most efficiently identified patients with disease
progression with area under the ROC curve being 0.805
(standard error = 0.066; 95% CI = 0.675-0.935) and 0.895
(standard error = 0.05; 95% CI = 0.797-0.993), respec-
tively (Figure 4). At a cut-off of 312.6 pg/mL, determined
from ROC curve for VEGF at BV2, we observed a sensitiv-
ity of 71.4% (95% CI = 42.0-90.4) and specificity of
71.4% (95% CI = 51.1-86.0) for predicting disease pro-
gression (Table 5). Further, at 355.4 pg/mL cut-off value
for VEGF at BV3, a sensitivity of 85.7% (95% CI = 56.2-
97.5) and specificity of 89.3% (95% CI = 70.6-97.2) was
achieved (Table 5). For the specific prediction of disease
progression, we observed very low sensitivities of 7.1%
and 21.4% at 100% specificity for the VEGF levels availa-
ble before second and third cycles of chemotherapy,
respectively.
Circulating plasma VEGF levels as a tumor marker: 
calculating specificity and sensitivity using receiver-
operating characteristics (ROC) curve
The median plasma VEGF level (25-75th quartile) was
265.7 pg/mL (155.7-408.0 pg/mL) in patients with
NSCLC (n = 134) and 74.5 pg/mL (40.3-132.0 pg/mL) in
controls (n = 100). This difference in VEGF levels in case
versus controls was highly significant (p < 0.0001; Table
1).
Table 4: Value distribution of VEGF in various response groups of NSCLC patients during first-line chemotherapy
P
Biomarkers (unit) Remission median 
(range)
No Change median 
(range)
Progression median 
(range)
R+NC vs P R vs NC+P
VEGF BV1 (pg/mL) 364.0 (136.6-868.0) 180.5 (70.6-546.0) 286.4 (72.6-522.6) 0.589 0.083
VEGF BV2 (pg/mL) 144.0 (34.6-588.4) 237.8 (52.1-431.0) 325.2 (158.4-612.1) 0.001 0.016
VEGF BV3 (pg/mL) 119.0 (26.0-571.0) 269.7 (51.0-526.0) 402.8 (174.6-811.0) 0.001 0.001
VEGF BV1-2 (Dec%) 41.6 (2.2-86.8) -6.6 (-90.6-64.5) -18.5 (-118.2-2.7) 0.0001 0.0001
VEGF BV1-3 (Dec%) 63.0 (17.2-93.1) -3.2 (-142.2-53.0) -41.0 (-140.5- -17.8) 0.0001 0.0001
VEGF BV2-3 (Dec%) 12.7 (-62.4-87.1) -21.2 (-33.6-33.8) -15.3 (-66.3-5.3) 0.0268 0.0052
BV1, BV2, and BV3, baseline VEGF levels before therapy cycle 1 to 3, respectively; BV1-2, BV1-3 and BV2-3, kinetics of baseline VEGF levels from 
cycles 1 to 2, 1 to 3 and 2 to 3, respectively; Dec%, decrease in percent (negative numbers meaning increase of the VEGF levels). P values by 
Wilcoxon test indicate differences between patients with progressive disease (P) and those having remission and stable disease (R+NC; evaluation 
1) as well as between patients with remission (R) and those having progressive and stable disease (P+NC; evaluation 2).Page 6 of 12
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concentration in patients that did not overlap with the
control VEGF value would be ideal. Receiver-operating
characteristics (ROC) curve was, therefore, generated for
calculating the sensitivity and specificity of VEGF as a
tumor marker at a selected cut-off value. The cut-off value
of plasma VEGF levels was determined as 145.4 pg/mL
using the ROC analysis (area under the curve = 0.8799;
standard error = 0.0213; 95% CI = 0.8381-0.9216; Figure
5). At this cut-off, plasma levels of VEGF reached a sensi-
tivity of 79.8% and a specificity of 79.0% for the detection
of NSCLC. Further, at 95% specificity, we could detect
NSCLC with a sensitivity of 59.7% (VEGF cut-off = 237.0
pg/mL).
Circulating plasma VEGF levels in correlation with various 
clinicopathological factors
The relationships between various clinicopathological
factors and plasma VEGF levels in the patients with lung
cancer are shown in Table 2. VEGF levels were signifi-
Distribution of plasma VEGF levels in various response groupsFigure 2
Distribution of plasma VEGF levels in various response groups. Median and interquartile range along with minimum 
and maximum values and outliers of the baseline values of the VEGF before start of therapy cycle 1 (pre-treatment; BV1), cycle 
2 (BV2), and cycle 3 (BV3) are given.
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mL (218.0-484.5 pg/mL) as compared to patients with
tumor size <3 cm (172.4 pg/mL (93.0-262.0); p < 0.001).
Plasma VEGF levels were found to be higher in patients
with poor performance status (PS), i.e. with a PS 2-3 com-
pared to those with PS of 1 and in patients with higher
nodal status (N2-N3) than those with N0-N1. However,
these levels did not achieve statistical significance (p =
0.062 for PS and p = 0.082 for nodal status). There was no
association between plasma VEGF levels and age, sex,
smoking and tobacco habits, histology, and stage (Table
2).
Discussion
Tumor cells secrete and synthesize a number of ang-
iogenic factors which play an important role in tumor
proliferation, spread and metastasis. VEGF, one of the
most potent angiogenic factors, plays a central role in the
regulation of tumor angiogenesis. The current interest in
targeted therapies against VEGF and its receptors has gen-
erated the need to study the course of this circulating ang-
iogenic protein molecule during chemotherapy, to find
out whether VEGF can be used in predicting prognosis
and in monitoring response to therapy. Previously, some
tumor biomarkers, including CYFRA 21-1, CEA and
nucleosomes [4-9] have been used for predicting progno-
sis and estimating response to therapy. However, till date,
none of them have been validated in a clinical setting. To
the best of our knowledge, this is the first study which
reports the kinetics of circulating VEGF levels during the
course of chemotherapy in an effort to predict insufficient
response to therapy and disease progression at an early
stage.
In this study, we analyzed the course of circulating plasma
VEGF levels at three different time points in 42 advanced
stage NSCLC patients receiving platinum-based chemo-
therapy. VEGF levels were measured before first (BV1),
second (BV2) and third (BV3) therapy cycle. These levels
were then correlated with available clinical information to
know whether VEGF levels could predict insufficient ther-
apy response or disease progression. We found that
patients with remission had significantly lower VEGF lev-
els at BV2 and BV3 as compared to patients with no
change or progression. However, at BV1, patients who
went into remission had higher VEGF levels than those
with no change or progression. Further, to correlate any
change in VEGF levels with therapeutic response, the
kinetics of VEGF levels during the course of chemotherapy
was monitored. We observed a stronger decrease in VEGF
levels from cycle 1 to 2 (BV1-2), from cycle 1 to 3 (BV1-3),
and from cycle 2 to 3 (BV2-3) in patients with remission
when compared to those with no change or progression.
Our results with VEGF are in accordance with the hypoth-
esis that, when monitoring the efficacy of cytotoxic ther-
apy, a substantial decrease in the levels of tumor marker
often correlates with response to therapy whereas an
increase or an insufficient decrease are generally associ-
ated with no response or disease progression. In our
study, it was noteworthy that a significant difference in
VEGF levels was observed in the response group before the
start of the second therapy cycle. In a few patients who
went into remission, we observed a step fall in VEGF levels
to just above the reference range within this short time
frame. This decrease in VEGF levels in responders may be
due to the effect of cytotoxic agents on tumor cells, either
by killing them or by reduction of cellular turnover, lead-
ing to a decrease in the number of cells synthesizing and
secreting various angiogenic proteins, including VEGF. In
this study, it was decided to evaluate VEGF levels after 2
weeks of first and second chemotherapy cycle. At such
time points, it could be expected that no significant drug
levels would be in circulation and that therefore, VEGF
levels will reflect angiogenic activity of the residual tumor
mass.
There are few studies which measured serum VEGF levels
before and after chemotherapy and the data is conflicting.
In a cohort of 29 patients with lung cancer, serum VEGF
levels were measured before and after cisplatin-based
chemotherapy [12]. A significant decrease in VEGF levels
Table 5: Diagnostic profiles of VEGF levels available before second and third cycles of chemotherapy for the prediction of cancer 
progression or response to therapy
AUC Cut-off Sensitivity % Specificity % LR
(95% CI) VEGF (pg/mL) (95% CI) (95% CI)
Evaluation 1 (R + NC vs P)
VEGF BV2 0.805 (0.675-0.935) 312.6 71.4 (42.0-90.4) 71.4 (51.1-86.0) 2.5
VEGF BV3 0.895 (0.797-0.993) 355.4 85.7 (56.2-97.5) 89.3 (70.6-97.2) 8.0
Evaluation 2 (R vs NC + P)
VEGF BV2 0.724 (0.553-0.893) 232.1 76.9 (55.9-90.2) 75.0 (47.4-91.7) 3.1
VEGF BV3 0.817 (0.679-0.956) 261.0 76.9 (55.9-90.2) 75.0 (47.4-91.7) 3.1
BV2, and BV3, baseline VEGF levels before therapy cycle 2 to 3, respectively; AUC, area under receiver operating characteristic
(ROC) curve; 95% CI, 95% confidence interval; LR, likelihood ratio; R, remission; NC, no change; P, progression.Page 8 of 12
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there was an increase in VEGF levels, an observation sim-
ilar to ours. In another study, no difference in serum VEGF
levels was observed from samples taken before first cycle
after 24 hours and 48 hours of cisplatin-based chemother-
apy in NSCLC patients [13]. Similarly, in a study of
advanced NSCLC patients on cisplatin and gemcitabine
regimen, no difference in serum VEGF levels was observed
before first and after 3rd cycles of chemotherapy [14]. In a
phase II study of stage III NSCLC patients on concurrent
chemoradiation given with celecoxib (COX-2 inhibitor),
serum VEGF levels did not predict response [15]. Circulat-
ing VEGF levels were also used for predicting response in
NSCLC patients on second-line chemotherapy. Yoshim-
oto et al. [16] measured serum VEGF levels before and
after second-line gefitinib therapy in 52 NSCLC patients
and observed no significant change after the treatment,
even in responders. In a multi-centric phase II study of 58
NSCLC patients on second-line treatment, a decrease in
serum VEGF levels after two cycles was significantly asso-
ciated with clinical response [17]. Circulating VEGF levels
have also been monitored during the course of chemo-
therapy in SCLC patients. Tas et al. [18] measured VEGF
levels before first cycle and after 2nd cycle of chemotherapy
in 34 SCLC patients. There was no significant difference in
serum VEGF levels before after cytotoxic therapy (18). In
another study, a non-significant increase in serum VEGF
levels was observed in both responders and non-respond-
ers after 3rd cycle of chemotherapy in a group of 39 SCLC
patients [19].
Recently, a number of studies have been done where pre-
treatment VEGF levels were correlated with progression-
free survival (PFS), overall survival (OS), and response to
treatment in lung cancer patients being treated with anti-
angiogenesis drugs alone or in combination with conven-
tional chemotherapy. In a recent study by Hanrahan et al
[20] pre-treatment VEGF levels were correlated with PFS
in three randomized phase II trials in advanced NSCLC.
They found that, in NSCLC patients on second/third line
treatment, those having low baseline plasma VEGF level
had a significantly superior PFS when treated with vande-
tanib (VEGF receptor/EGFR receptor inhibitor) mono-
therapy compared with gefitinib monotherapy. Similarly,
in a Japanese study, baseline plasma VEGF levels were
lower in patients who experienced clinical benefit after
vandetanib treatment [21]. Both studies suggest that
determining pre-treatment circulating VEGF levels may
have the potential to identify patients who would derive
benefit from first-line targeted therapy with vandetanib.
In contrast to this, in the Eastern Cooperative Oncology
Group 4599 trial of carboplatin-paclitaxel with or without
bevacizumab in NSCLC, high baseline plasma VEGF were
associated with a greater response rate with the use of bev-
acizumab but not with improved survival [22]. We also
observed a greater response rate in patients with higher
pre-treatment plasma VEGF levels in NSCLC patients
treated with platinum-based chemotherapy.
There are few reports available correlating pre-treatment
VEGF levels with response to therapy and overall survival
of patients treated by conventional chemotherapy. In a
study on 52 advanced stage NSCLC patients treated with
cisplatin plus vinorelbine, no correlation between pre-
treatment serum VEGF levels and response to therapy was
observed [23]. This observation is similar to ours on
NSCLC patients treated with platinum doublets. In con-
trast, Laack et al [24] reported a significant correlation
between pre-treatment serum VEGF levels and response to
therapy in metastatic NSCLC patients treated in a rand-
omized phase III trial comparing gemcitabine plus vinor-
elbine (GV) and gemcitabine plus vinorelbine plus
cisplatin (GVP). Data regarding association of VEGF levels
with survival in NSCLC is conflicting, some studies show-
ing a correlation [25-27] whereas other not being able to
do so [15,28,29].
In the present study, we observed a significant difference
in overall survival time between patients with remission
as compared to patients with no change or progression.
Receiver-operating characteristics (ROC) curves for an early estimation of response to therapy by plasma VEGF levels available befo  the st t of therapy cycle 1 (BV1), cycl  2 (BV2), and cycl  3 (BV3)Figure 3
Receiver-operating characteristics (ROC) curves for 
an early estimation of response to therapy by plasma 
VEGF levels available before the start of therapy 
cycle 1 (BV1), cycle 2 (BV2), and cycle 3 (BV3).
BV1
BV3
BV2
Area under  the curve
0.339
0.724
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BMC Cancer 2009, 9:421 http://www.biomedcentral.com/1471-2407/9/421During the estimation of therapy response, patients are
generally grouped into responders (patients with remis-
sion) and non-responders (patients with stable disease or
progression). To increase the overall survival of the
patients, it is of utmost importance to find the group of
patients, at an early stage of their treatment, who are either
(i) going to respond to the treatment or (ii) going to
progress to a more advanced stage of disease. For both
these groups, it would be necessary to focus on the mark-
ers already being available before start of the second
course of the treatment. This could be helpful in the better
management of the cancer patients as an early prediction
of response to therapy or disease progression can be used
to either intensify treatment or change the treatment plan.
Therefore, we conducted two different evaluations of
plasma VEGF levels, available before cycle 2 of therapy
(BV2), to address both clinical questions.
For evaluation 1 (R+NC versus P), we selected a VEGF
(BV2) cut-off levels of 312.6 pg/mL from the ROC curve
(area under the curve = 0.805). At this cut-off, we were
able to diagnose disease progression with a sensitivity and
specificity of 71.4%. While for evaluation 2 (R versus
NC+P), VEGF levels before cycle 2 (BV2) was able to pre-
dict an insufficient therapy response with a sensitivity and
specificity of 76.9% and 75.0%, respectively, when a cut-
off of 232.1 pg/mL was applied. Interestingly, the kinetics
of VEGF form cycle 1 to 2 (BV1-2) and cycle 1 to 3 (BV1-
3) also gave significant information for predicting disease
progression as well as insufficient response to therapy.
Although, our sample size was a limitation, the results
show that monitoring the levels of circulating VEGF dur-
ing the course of cytotoxic therapy can predict insufficient
response to therapy and disease progression. Earlier stud-
ies have not evaluated measurement of levels of VEGF at
defined intervals during the initial treatment phase for
predicting insufficient response to therapy and disease
progression in NSCLC patients. So, a large-scale prospec-
tive validation study is needed to confirm the relevance of
the current findings presented here.
Further, we compared plasma VEGF levels in 134 NSCLC
patients and 100 controls. Also, correlation with various
clinico-pathological factors and VEGF was looked at. This
study highlights a few significant findings: (a) plasma
VEGF levels were significantly higher in patients with
NSCLC as compared to controls; (b) significant associa-
tion was observed between plasma VEGF levels and tumor
size. Also, there was some evidence to suggest a correla-
tion between plasma VEGF levels and performance status,
and nodal involvement. However, these associations did
not reach the level of statistical significance.
Receiver-operating characteristics (ROC) curve to calculate sensitivity and specificity of plasma VEGF levels as a tumor marker in dvanc d non-sma l cell lung cancerFigure 5
Receiver-operating characteristics (ROC) curve to 
calculate sensitivity and specificity of plasma VEGF 
levels as a tumor marker in advanced non-small cell 
lung cancer.
Area under  the curve = 0.878
Receiver-operating characteristics (ROC) curves for predict-ing d s ase progression by pla ma VEGF levels available b fore th start of therapy cycle 1 (BV1), ycle 2 (BV2), and cycl  3 (BV3)Fi ure 4
Receiver-operating characteristics (ROC) curves for 
predicting disease progression by plasma VEGF lev-
els available before the start of therapy cycle 1 (BV1), 
cycle 2 (BV2), and cycle 3 (BV3).
BV1
BV3
BV2
Area under  the curve
0.552
0.805
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BMC Cancer 2009, 9:421 http://www.biomedcentral.com/1471-2407/9/421Conclusion
In conclusion, to our knowledge, this is the first study
investigating the initial changes in plasma VEGF levels for
the prediction of insufficient response to therapy and dis-
ease progression in advanced NSCLC patients during first-
line chemotherapy. Our results clearly show the relevance
of circulating VEGF levels in differentiating responders
from non-responders to therapy and in predicting disease
progression. In future, such analyses could also be used
for monitoring of tumor recurrence.
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